{"filing":{"accession_number":"0001493152-26-026696","cik":"0001763950","ticker":"LTRN","company_name":"Lantern Pharma Inc.","form":"8-K","filing_date":"2026-06-02","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1763950/000149315226026696/form8-k.htm"},"events":[{"id":7564,"run_id":6647,"accession_number":"0001493152-26-026696","anchor_item_number":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"summary":"The filing discloses a presentation used on June 1, 2026 regarding the Harmonic™ Phase 2 clinical trial for LP-300, filed under Item 7.01 (Regulation FD Disclosure). While clinical trial updates can be material to pharmaceutical investors, the 8-K provides no substantive detail about trial results, efficacy, safety, or outcomes—only that a presentation was used in discussions. Without disclosure of actual clinical data or trial milestones, this appears to be a routine disclosure of investor communications rather than a specific material event (e.g., trial completion, positive/negative results, or regulatory action).","company_name":"Lantern Pharma Inc.","ticker":"LTRN","filing_date":"2026-06-02","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":3701,"accession_number":"0001493152-26-026696","item_number":null,"item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The filing discloses a presentation used on June 1, 2026 regarding the Harmonic™ Phase 2 clinical trial for LP-300, filed under Item 7.01 (Regulation FD Disclosure). While clinical trial updates can be material to pharmaceutical investors, the 8-K provides no substantive detail about trial results, efficacy, safety, or outcomes—only that a presentation was used in discussions. Without disclosure of actual clinical data or trial milestones, this appears to be a routine disclosure of investor communications rather than a specific material event (e.g., trial completion, positive/negative results, or regulatory action).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:41:05.150243+00:00","company_name":"Lantern Pharma Inc.","ticker":"LTRN","filing_date":"2026-06-02"}]}